Helping your patients live in harmony with creatures great and small

Intended for UK healthcare professionals
Ryaltris® Live like you
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd medical_information@glenmarkpharma.com or call 0800 458 0383
Glenmark
Intended for UK healthcare professionals
Ryaltris® Live like you

Ryaltris opens
up more than
just airways1,2

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd medical_information@glenmarkpharma.com or call 0800 458 0383
Glenmark

Moderate-severe allergic rhinitis (AR)

AR is common and its prevalence is increasing.3 It can be perennial (where symptoms are typically chronic) or seasonal (with intermittent symptoms triggered by various pollens or spores).3

Compared to patients with mild disease, patients with moderate-severe AR experience more frequent and longer-lasting symptoms, and are likely to have many allergenic triggers.4

These triggers include:3

...

Tree, grass and
weed pollens

...

House dust mites

...

Animal dander

...

Mould spores

Contact us to request a pollen & spore poster for your practice

The ARIA guidelines define
moderate-severe AR as:5

...

Severe ongoing
nasal stuffiness with
congestion and
sinus drainage

...

Impairment of daily
activities (one or more
of sleep, work, school,
troublesome symptoms)

AR can significantly reduce patient quality of life and can affect their school or work attendance.6 Additionally, sleep can be disturbed in 50-80% of sufferers, leading to daytime tiredness, poor concentration and mood disorders.7

About Ryaltris®

What is Ryaltris®?

Ryaltris® is indicated in adults and adolescents 12 years of age and older for first-line treatment of moderate to severe nasal symptoms associated with AR.1

The active ingredients in Ryaltris® are olopatadine (a potent, selective antihistamine) and mometasone furoate (a topical corticosteroid with local anti-inflammatory properties).1

Recommended dose

The Ryaltris® recommended dose for adults and adolescents (12 years and older) is two actuations (sprays) in each nostril twice-daily (morning and evening).1

Please consult the Summary of Product Characteristics for more information.

Ryaltris® contains

What you can expect with Ryaltris®

...
The only fixed-dose combination nasal spray for first-line treatment of moderate-severe nasal symptoms associated with AR1
...
Symptom relief within 10-15 minutes* and lasts for 24 hours with twice-daily dosing2,8,9
*Findings from one environmental exposure chamber study and two large randomised controlled trials2,8,9
...
A fine mist spray, with each bottle containing 240 actuations1,10
  • Recommended dose: 2 sprays in each nostril twice-daily1
Check Icon
Generally well tolerated; the most commonly-reported adverse reactions are dysgeusia, epistaxis and nasal discomfort1,2,11
...
Provides a potential NHS cost acquisition saving of over £1.1 million a year vs. Dymista®12
Patients

Support for healthcare professionals and payers

Glenmark Pharmaceuticals has developed a range of support items to help clinicians manage their patients and to support Healthcare Organisations in their decision making.

For HCPs

‘How to use’ video

‘How to use’ video

Patient tear-off pad

Patient tear-off pad

Pollen & spore poster

Pollen & spore poster

Contact us to request more information about any of these items, or to request a visit from a Glenmark Pharmaceuticals representative.

For payers

Formulary pack

Formulary pack

Contact us for more information about payer support and how Glenmark Pharmaceuticals can help your local health area.

Support for patients

When you prescribe Ryaltris®, your patients have access to clear information and support to ensure they take their medication correctly. This information is additional to the Patient Information Leaflet (PIL) that comes in every Ryaltris® pack, and is not intended to replace the PIL.

Patient tear-off pad

Patient tear-off pad

You can provide your patients who have been prescribed Ryaltris® with a tear-off sheet covering key information and advice about their Ryaltris® treatment. Click here to download.

Website

Website

Patients prescribed Ryaltris® can access a dedicated website with information, advice and guidance to help them manage their treatment and their AR. Click here to view.

‘How to use’ video

‘How to use’ video

You can use this to facilitate training with your patients who have been prescribed Ryaltris®. The film can also be accessed from the patient website. Click the play icon to view.

References:
  1. Ryaltris Summary of Product Characteristics.
  2. Gross GN, et al. Ann Allergy Asthma Immunol 2019;122:630-638.
  3. NICE CKS. Allergic rhinitis. Available at https://cks.nice.org.uk/topics/allergic-rhinitis/.
  4. Price D, et al. Clin Transl Allerg 2015;5:39.
  5. Sussman G, et al. CMAJ 2010;182(9):935-937.
  6. Scadding GK, et al. Clin Exp Allergy 2017;47:856–889
  7. Lipworth B, et al. NPJ Prim Care Respir Med 2017;27(1):3.
  8. Hampel FC, et al. Allergy Asthma Proc 2019;40(4):261–272.
  9. Patel P, et al. Ann Allergy Asthma Immunol 2019;122(2):160–166.
  10. Ryaltris Patient Information Leaflet.
  11. Segall N, et al. Allergy Asthma Proc 2019;40(5):301–310.
  12. Data on File. Ryal/008/2023/001. August 2023.
Ryaltris®

Ryaltris information request form

Please fill out your details and tick the boxes relevant to you if you would like to receive Ryaltris support materials, or a visit from your Glenmark representative.

Your details:

*Mandatory fields

I would like to receive:

Yes**

**By ticking ‘Yes’ you are indicating your consent to receive promotional materials from Glenmark Pharmaceuticals Europe Limited. Your details will be handled strictly in accordance with the applicable privacy laws and our privacy notice available at glenmarkpharma.com/privacy-notice/, including your right to opt out from all communication at any time. There is no obligation to hold a meeting with a representative when the form is submitted.

By clicking ‘Submit’ I consent to the use of my Personal Information provided on this form being stored and used for the purpose of following up on the request in accordance with the Glenmark Pharmaceuticals Europe Limited Terms of Use and Privacy Notice

Prescribing information and AE reporting

By clicking this link, you are leaving the Ryaltris® website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to continue, please click ‘Continue’, otherwise click ‘Stay on page.’